Seres Therapeutics, Inc.

MCRB Nasdaq SEC CIK 1609809
Follow Seres Therapeutics Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Revenue, last quarter $593K +68.9% vs same quarter last year
Net income −$16.3M −298.5% vs same quarter last year
EPS, diluted −$1.63 −273.4% vs same quarter last year
Operating cash flow −$10.5M −574.9% vs same quarter last year
Revenue by quarter
$0
$0
$0
$351K
$438K
$358K
$736K
$593K
Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income14 fiscal years
  • Revenue
  • Net income
−$300M−$200M−$100M$0$100M$200MFY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearRevenueNet income
FY25$789K$5.7M
FY24$0$136K
FY23$0−$113.7M
FY22$7.1M−$250.2M
FY21$143.9M−$65.6M
FY20$11.9M−$89.1M
FY19$27.2M−$70.3M
FY18$26.9M−$98.9M
FY17$32.1M−$89.4M
FY16$21.8M−$91.6M
FY15$0−$54.8M
FY14-−$16.7M
FY13-−$6.1M
FY12--
MarginsShare of revenue
  • Operating margin
  • Net margin
−15000%−10000%−5000%0%5000%FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearOperating marginNet margin
FY25−11910.1%721.9%
FY24--
FY23--
FY22−2524%−3509.5%
FY21−44.8%−45.6%
FY20−740.8%−749.2%
FY19−264.4%−258.5%
FY18−372.6%−367.6%
FY17−284.7%−278.4%
FY16−426.5%−420.7%
FY15--
FY14--
FY13--
FY12--
Free cash flowOperating cash flow minus capital expenditure
−$300M−$200M−$100M$0$100MFY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearFree cash flow
FY25$865K
FY24−$149M
FY23−$125.3M
FY22−$238.6M
FY21−$2.9M
FY20−$94.2M
FY19−$77.5M
FY18−$64.8M
FY17−$80.2M
FY16$22.4M
FY15−$45.2M
FY14−$11.4M
FY13−$5.5M
FY12-
Net margin vs the sectorMedian of Healthcare companies filing with the SEC
  • Seres Therapeutics
  • Healthcare median
−4000%−2000%0%2000%FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearSeres TherapeuticsHealthcare median
FY25721.9%−30.6%
FY24-−47%
FY23-−58%
FY22−3509.5%−80.4%
FY21−45.6%−71.8%
FY20−749.2%−62.2%
FY19−258.5%−46.2%
FY18−367.6%−49.6%
FY17−278.4%−45.9%
FY16−420.7%−36%
FY15-−37.8%
FY14-−35.5%
FY13-−37.1%
FY12-−29.1%